FundamentalXR is tackling a simple but important problem: advanced eye therapies need surgeons who can perform highly specialised procedures safely and consistently before treatments can scale.
The company has developed a simulation for subretinal gene therapy delivery, a procedure that requires precise surgical control and confidence around delicate retinal tissue. As complex therapies advance, the ability to train clinicians consistently may become a key factor in how quickly treatments move from scientific promise to wider clinical use.
FundamentalXR’s technology combines virtual reality with haptic feedback, allowing surgeons to practise both the visual and physical elements of a procedure in a controlled setting. Specialist procedures cannot rely only on conventional training models, which are often limited by operating theatre access, geography and the availability of suitable cases.
The company is therefore targeting an important part of the adoption pathway for new therapies. Its platform is designed to help reduce training friction, support procedural consistency and give healthcare providers a more scalable way to prepare surgical teams.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
